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Periodontal and implant-related diseases comprise a group of chronic conditions that are 
driven by bacterial challenge from the retention of supragingival plaque and the formation of 
biofilm in the subgingival niche of the periodontal environment. 
 
Chronic periodontitis is linked to a microbiota comprising a small group of around 15 of the 
500 plus species that inhabit the oral cavity (96).  The progression of periodontal disease 
either as a consequence of lack of treatment (6,71,84,87,140,144) or inadequate long-term 
management (11,104) results in ongoing attachment loss and bone resorption which, with 
time, will compromise patient-related outcomes such as tooth retention, aesthetics and 
dental function. 
 
Dental implants are also susceptible to inflammatory diseases that are caused by the 
accumulation of biofilm.  These conditions are categorised into those that are limited to the 
peri-implant soft tissues (peri-implant mucositis) and those that also affect the alveolar bone 
support (peri-implantitis).  Peri-implant mucositis is a reversible, inflammatory lesion 
affecting the marginal soft tissues that surround osseointegrated dental implants but does 
not involve the resorption of the supporting bone.  Conversely, peri-implantitis affects the 
supporting bone as well as the surrounding mucosa of a functioning implant (1,85 166). 
 
The conventional treatment of periodontal and peri-implant diseases involves cause-related 
therapy comprising a home-based oral hygiene programme, together with professional 
management (scaling, root and implant surface instrumentation) which may be undertaken 
non-surgically or with surgical access to the affected sites.  These anti-infective, professionally 
delivered treatments are, for the majority of patients, effective and lead onto longer-term 
3 
 
programmes of supportive periodontal care (SPC).  Such recall programmes are an integral 
part of periodontal management (3) and are critical to prevent the progression of chronic 
diseases when they have been successfully stabilised following treatment.  Even when teeth 
have been lost during the active stage of treatment, further tooth loss may be prevented if 
there is compliance with appropriate SPC (7,8,24,35,101,115).  SPC is, therefore, largely 
founded on the chronic nature of the disease, the ability or inability of the patient to maintain 
plaque levels that are consistent with stability, and the willingness and ability of the clinician 
to deliver the appropriate management (44). 
 
The aims of this paper are to outline the goals of SPC programmes both for chronic 
periodontitis and peri-implant diseases, to review the clinical- and cost-effectiveness of 
periodontal recall and to consider the additional treatment options available to the clinician 
when these goals have not been met.  Within the context of this paper, the association of the 
recall programmes is with SPC rather than with the prevention of periodontal disease in 
otherwise healthy patients (147). 
 
The goals of periodontal recall 
The overarching goals of periodontal recall are to ensure that the periodontal or peri-implant 
tissues are maintained in a state of health, with the achievement of an acceptable degree of 
disease stability, patient comfort and oral function.  There are differences of course as to how 
this goal might be achieved for periodontally affected teeth compared to implants. SPC for 
patients with periodontal disease starts at the post-treatment stage whereas for implants, 
the SPC commences after placement and at a point where no inflammatory change may yet 
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be present. With this in mind, the aims of recall for both scenarios are broadly the same and 
to: 
 
 minimise or halt the progression of inflammatory disease; 
 avert or postpone the loss of natural teeth (101) or implants, limiting the potential 
damaging biological (20), psychological (106) and financial consequences; 
 provide the clinician with an opportunity to identify and treat pathology at an early 
stage in order to improve long-term prognosis and treatment outcomes (30). 
 
In order to identify failing SPC at the patient level it is crucial that the parameters of success 
are first considered.  At present there are no universally agreed clinical outcomes perhaps 
mainly because of the complex nature and progression of periodontal and peri-implant 
diseases along with their multifactorial aetiology.  Further, the criteria for success may well 
differ between the clinicians’ and patients’ perspectives. 
 
The patients’ concerns predominantly relate to tooth loss and ongoing functionality, although 
the impact of SPC and indeed periodontal treatment on these parameters are infrequently 
reported (66).  Such patient-centered outcomes may be either too complicated or long-term 
to be measurable in real-time clinical trials and conversely, the outcomes which concern 
clinicians may be difficult to relate to the contemporary concept of patient-centered care.  
Further, the current lack of clear definition between periodontal or peri-implant health makes 
the identification of success of SPC in the long-term quite challenging and we still rely 
predominantly on clinical and radiographic outcomes to ascertain levels of success and failure 
(9,18). 
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Periodontal tissues 
Whilst unequivocally it is clear that the presence of plaque following periodontal intervention 
predisposes to progression of clinical attachment loss (6,7), there is a lack of empirical 
evidence to suggest a specific, minimum threshold plaque level that must be achieved 
perhaps because quantification of plaque is not an accurate surrogate marker to predict 
disease progression (28).  Because of the complexity of the microflora associated with the 
aetiology of periodontal disease and the unequivocal role of the host response in determining 
risk and susceptibility, it is impossible and probably unhelpful to try to identify a universal 
minimum plaque level; the preferred option is to consider plaque control at the patient level 
whilst considering other risk factors such as smoking.  Nevertheless, typical plaque scores of 
between 20-40% have been suggested as the goal for the majority of patients post-treatment 
and by implication throughout SPC (82). 
 
Given the accepted influence of bacteria on periodontal and peri-implant diseases, there 
must be a strong focus on anti-infective measures.  Although the biofilm rapidly reforms 
following debridement, repopulation of bacteria to baseline levels following periodontal 
treatment has been found to occur generally between 3-6 months (138), which assists in 
determining recall regimens. It follows that an increased frequency of recall should favour 
stability of the periodontal tissues. 
 
Bleeding on probing has also been proposed as one of the most confident outcomes for 
determining appropriate intervals between periodontal SPC recall appointments given their 
strong negative predictive value for periodontal disease.  Scores between 10-20% have been 
proposed as the threshold below which a significant reduction in disease progression and 
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subsequent attachment loss may be observed and stability and success may be more likely 
(74,80). 
 
Periodontal sites with residual probing depths of <5mm and those at which a reduction in 
probing depth of 2mm is observed during SPC following periodontal treatment has been 
identified as a clinically relevant minimal threshold to enable the site to be identified as being 
non-risk of future progression (92) and the patient classified as a positive responder to SPC 
(114).  The specific criteria used to define progression does vary however, with others 
suggesting for example, that progression of disease (and presumably failing SPC) is consistent 
with > 2 teeth showing > 3mm of interproximal attachment loss between 2 time points 
(92,150) or interproximal sites losing >1.5mm attachment during longitudinal monitoring 
(86).  A critical search of the literature shows that consensus regarding the definition of 
success of SPC is clearly lacking (86,92,114,127,150).  Clinically, of course, at the site-specific 
level, varied responses are inevitable depending, for example, on the initial depth of pocket 
and clinical attachment level, and also whether interventions are of a surgical or non-surgical 
nature (63). At sites where bleeding co-exists with an increase in pocket depth of over 1mm, 
then that site has a positive predictive value of 87% for subsequent development of bone and 
attachment loss (27). 
In summary, therefore, the goals of successful periodontal recall regimens for teeth may be 
achieved with (114,150): 
 
 Stabilisation of plaque scores at 20-40%; 
 Stabilisation of bleeding scores at 10-25%; 
 Probing depth reductions and maintenance between 1-2mm (at 30% of sites); 
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 Residual probing depths of <5mm; 
 Gains in clinical attachment levels. 
 
Peri-implant tissues 
The goals of recall specific to peri-implant tissues are associated with the prevention of peri-
mucositis and peri-implantitis with the prevalence of both conditions being 43% and 22% 
respectively (43).  A key aim of recall is to allow an opportunity for early identification of the 
onset of inflammation and, therefore, in halting the progression of peri-mucositis to peri-
implantitis (37).  Again, whilst there is no consensus regarding the measures to assess the 
long-term performance of implants other than simply through survival or loss (99), there are 
various clinical parameters which may be used to assess the status and stability of the peri-
implant tissues at recall. 
 
The criteria for successful SPC can be aligned to those outlined for periodontal disease by 
looking to maintain optimum plaque control around implant sites recognising that biofilm 
removal will address the key aetiological factors in peri-implant disease (13).  Again, absence 
of bleeding on probing has a high negative predictive value and is a particularly strong 
indicator of stability of the peri-implant tissues (81,89).  Indeed, bleeding at implant sites is 
similarly predictive of active disease as it is around natural teeth (128). 
 
The interpretation of probing depths can vary according to the depth of initial implant 
placement.  The identification of a deep pocket alone with no other accompanying signs does 
not necessarily indicate the presence of pathology and concerns regarding potential 
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detrimental effects to the peri-implant mucosal seal have been shown to be unfounded 
provided a consistent probing force of no greater than 0.25N is applied (46). 
 
Supracrestal implant platform position will likely have minimal pocketing at the time of 
placement when compared with subcrestal placement, and as such it has been suggested that 
longitudinal comparison of probing depths from baseline may best indicate whether there is 
disease progression (91).  A minimum threshold of 1.0mm increase in probing depth has been 
suggested to classify a site with ongoing attachment loss (73).  Further, any mobility of 
implants seen during SPC suggests a failure of osseointegration and implant removal is 
indicated.  Mobility of implants during SPC, therefore, is of little use in early identification of 
peri-implantitis (62) although suppuration maybe more helpful in determining SPC 
management as it has been suggested as being indicative of bone loss of ≥3 implant threads 
(125). 
 
The diagnosis of developing peri-implantitis can be confirmed through the identification of 
marginal crestal bone loss around the implant (130).  Baseline radiographs should be taken at 
placement, and annually during SPC thereafter (40).  There is a need to exercise caution 
regarding the appearance of bone loss adjacent to implants - coronal voids from over-
aggressive countersinking, surgical trauma, and even the inevitable consequence of loading 
may all predispose to marginal crestal bone loss (135). 
 
In summary, therefore, the goals of successful periodontal recall regimens for implants may 
be achieved with (108): 
1. Probing depths no greater than 5mm; 
9 
 
2. Absence of bleeding on probing; 
3. Absence of implant mobility; 
4. Absence of pain/dysaesthesia; 
5. Absence of continuous radiolucency surrounding implant; 
6. Annual vertical loss of bone height no greater than 0.2mm. 
 
The clinical effectiveness of supportive periodontal care 
The literature is replete with studies of patients with chronic periodontitis who have been 
subjected to programmes of SPC.  Our group has previously undertaken a systematic review 
to identify the more robust of these clinical trials and with the primary objective of identifying 
any differences between those managed intensively in specialist practice and those seen in 
the general dental services (54).  The inclusion criteria for the systematic review were studies: 
 
 of patients with chronic periodontitis;  
 of SPC following surgical and non-surgical treatment in specialist and, or general care; 
 with at least 12 months follow-up; 
 with clinical attachment as the primary outcome measure. 
 
We have recently updated our search but found no additional studies that fulfil these criteria.  
The observations from the 14 original studies, however, provide robust evidence for the 
potential clinical effectiveness of SPC (Table 1) and it is important for the clinician to be aware 
of the expectations of SPC before considering whether, over a period of time, their 
management at the patient or site levels can be considered a success or a failure. 
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The findings of the systematic review show clearly that patients who receive more frequent 
recall visits are likely to demonstrate less clinical attachment loss and even, in some instances, 
attachment gain when compared to those on irregular and less frequent programmes of care 
(7,38,72,75,105,110,126,162).  With regular SPC provided every 3 or 4 months, attachment 
change is predominantly in the range – 0.85 [loss] to +0.25 [gain] and this is sustainable over 
periods of up to 12 years (7,38,72,75,105,110,117,118,126,133,162).  Attachment loss occurs 
across buccal, lingual and interproximal sites and irrespective of whether the initial 
periodontal treatment was surgical, non-surgical or a combination of both 
(38,75,110,117,133,162).  There is, however, limited evidence to suggest that greater loss 
occurs when SPC follows surgical intervention (12). 
 
In response to the principal, focussed question of the systematic review (54) it was reported 
that frequent recall with a periodontist or dental hygienist in specialist care, or when provided 
as an intense programme in a dental school or hospital setting, generally leads to less 
attachment loss than when SPC is delivered by a general dentist (32,36,92).  This difference 
tends to disappear when general dentists are provided with a clear prescription of the SPC 
that they are expected to provide and even when there is a slight deterioration in plaque 
control over 12 months (112). 
 
Whilst these data are interesting and up to a point still provide the best available evidence 
for the expected outcomes of SPC, it is important to note that data are reported as group 
means (either at the full or part mouth level).  This does not allow identification of those 
specific unstable and deteriorating sites which would be better markers of where SPC is failing 
at the site level and thus allow the clinician to re-evaluate and, or redeliver aspects of SPC 
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without having to resort to intuition.  In contrast, in a 12-month study of 150 patients with 
moderate-to-advanced chronic periodontitis, SPC delivered in private practice was more 
effective than that provided in a dental school reducing sites with bleeding from 71% to 42%, 
reducing moderate (4-5mm) and deep (>6mm) pockets from 22% and 7% to 3% and 0% 
respectively, and reducing the number of sites with attachment loss of 4-5mm and >6mm 
from 31% and 24% to 18% and 11% respectively (36).  These population data provide valuable 
indication of the expectations and limitations of SPC on a patient level and also reinforce the 
concept that even with intensive SPC programmes, it is crucial to identify those individual 
sites where disease progression is likely.  The data from this study (36) and others (92) suggest 
that for sites with probing depths >6mm and with full mouth bleeding prevalent at >30% sites 
then there is a clear risk for disease progression. 
 
There is much less literature available to ascertain the effectiveness of SPC for dental implants 
and specifically the impact of SPC in preventing the progression of an established mucositis 
to peri-impalantitis.  A key finding from the 2014 European Workshop of Periodontology 
concluded that a lack of long-term supportive care in patients with mucositis was associated 
with an increased risk of peri-implantitis (73).  This confirmed earlier observations that the 
provision of regular SPC over 5 years was able to restrict considerably the progression of 
mucositis to peri-implantitis (Table 1) (37). 
 
The cost effectiveness of supportive periodontal care 
Having considered a number of treatment options for those patients who have sites that 
appear to be failing during SPC it is important to reflect on available literature that may 
provide some insight into the cost-effectiveness of these management strategies.  In doing 
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so, we will then be able to provide patients not only with a prediction of the long-term clinical 
outcomes but also a simple explanation for the estimate of the costs of achieving those 
outcomes and maintaining a periodontally stable dentition (49). 
 
Firstly, to assess the economic aspects of having SPC provided in general and specialist 
practice we have previously constructed a model to evaluate the cost-effectiveness of SPC 
using the data from the studies shown in Table 1 (54).  This model was constructed from the 
perspective of a single patient over a 30-year period, being managed in the UK, and with the 
outcomes being the loss of tooth years and clinical attachment.  SPC provided in specialist 
practice assumed 30-minute appointments with a dental hygienist and 3-monthly recall visits; 
SPC provided in general practice assumed 20-minute hygienist appointments with 6-monthly 
recall intervals and delivered both in private and public funded (State) care environments.  
Observations showed clearly, and perhaps not unexpectedly, that SPC achieves greater 
periodontal stability and higher rates of tooth retention when delivered more frequently in 
specialist practice when compared to provision by the general dental services.  This improved 
long-term outcome, however, comes at a greater cost to the patient shown by incremental 
cost-effective ratios (ICERs) which represent the difference in costs divided by the difference 
in effectiveness between any intervention and the next best alternative (161).  The ICER gives 
a measure of the cost per unit of effectiveness of implementing a more effective but more 
costly programme (161).  For example, for SPC in specialist practice, the ICER was €290 for 
one extra tooth year saved and €1500 for 1mm less attachment loss over 30 years.  Although 
this model was based on data from the UK, we later confirmed similar observations using data 
from across Europe, North America, Asia and Australasia (111).  In summary, SPC delivered by 
a periodontist is more effective but comes at a greater cost. 
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In terms of cost-effectiveness, the value of SPC cannot be over emphasised. Pretzl and co-
workers (116) used data from 98 patients who were in SPC for 10 years and found, 
unsurprisingly, that real costs for those who were regular attenders were greater than for 
infrequent attenders.  Crucially, however, the maintenance of a tooth through regular SPC is 
considerably cheaper than extraction and replacement with dentures, implants or bridges 
and so for patients with chronic periodontitis SPC is the most cost-effective option.  Indeed, 
for those patients who opt not to enrol in maintenance care, the cost of life-long SPC will 
equate approximately to the cost of extraction and replacement of only 3-4 teeth (50).  One 
suggested approach, therefore, is to stress the financial benefit of SPC to patients and with 
the view of using this as a potential ‘lever’ to improve compliance (116). 
 
There has been much less consideration of the health economics of supportive periodontal 
care for implants.  In one ‘real time’ study set in a private periodontal practice in Norway, the 
mean supportive implant care (SIC) cost / implant with peri-implantitis was €110 over the 
entire period of follow-up whereas the mean SPC cost / tooth with periodontitis was €35.  
These figures related to a mean cost/implant/year of €10.2 and mean cost/tooth/year of €2.1 
(48).  So although the most cost-effective method for providing supportive implant care has 
yet to be established (132) the costs of long-term supportive care for implants has been 
estimated to be higher than for natural teeth (48). 
 
What Next? 
It is now relevant to consider the strategies for managing a patient for whom SPC is failing 
under two broad headings: modification of predictive factors and adjunctive treatments.  In 
this context we define a predictive factor as one that is associated with a response or (in this 
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instance) a lack of response to a particular therapy (SPC) (29).  This implies that there will be 
a differential benefit from SPC depending upon the status of the predictive factor.  The 
modification of predictive factors is usually directed at the patient level whereas the use of 
adjunctive treatments is directed at the site level which depends on the sites at risk being 
identified.  For the purpose of this review we will make the assumption that any site that does 
not respond to SPC has already been assessed carefully for retained or reformed deposits and 
any appropriate retreatment to remove these deposits has been undertaken. 
 
Modification of predictive factors for supportive periodontal care 
The principal patient-level factors that might affect the outcome of SPC are the frequency of 
the recall visits, whether the patient is seen by a periodontist or their general dental 
practitioner, smoking habit, diabetes and compliance with the SPC programme. 
 
Smoking and diabetes 
The impact of smoking on limiting the benefit of periodontal treatment is well established (for 
reviews see 60,77,134,149) with, in general terms, inferior clinical outcomes being observed 
in patients who continue to smoke (26,113); a finding reinforced by data from a recent meta-
analysis of two longitudinal clinical trials (26).  Quitting smoking as part of periodontal 
management has a significant effect on resolving probing depths (compared to non-quitting), 
an effect that is maintained over 9 months of SPC (113).  Irrespective of smoking status, 
increased mean bleeding on probing during SPC has been shown, however, to be associated 
with disease severity and periodontal instability in both smokers and non-smokers, while 
smokers demonstrate lower mean BOP concomitantly with an increased prevalence of 
residual PPDs.  Further, bleeding on probing of < 20% in non-smokers and quitters may also 
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reflect disease stability, but more frequent SPC recall visits are still recommended for smokers 
in this category because of their higher proportion of residual probing depths (113,121).  
Clinical data may also be apparently contradictory: for example, in a retrospective cohort 
study of patients seen over 11 years for SPC, the prevalence of residual pockets > 5mm 
increased in heavy smokers when compared to light or non-smokers yet a shorter, 
prospective study over just 3 years demonstrated significantly shallower probing depths in 
non-smokers compared to smokers yet no significant difference in clinical attachment levels 
(51).  Perhaps of greater significance, however, was that neither probing depths nor 
attachment levels changed over 3 years when compared to the post-treatment baseline 
which reinforces the perception that whilst the clinical outcomes for smokers will likely be 
inferior to those for non-smokers, the progression of disease during SPC is unaffected by 
smoking status (51).  Nevertheless, in the absence of data that identifies the clinical status of 
smokers who quit during SPC, we must pursue the strategy of regular recall appointments for 
smokers with advice to quit the habit based on the knowledge that quitting as part of 
periodontal treatment has a significant benefit on clinical outcomes 
(25,26,60,77,113,134,149).  The association of smoking and compliance with SPC will be dealt 
with in a later section. 
 
Another familiar and unequivocal risk factor for periodontal disease is poorly controlled 
diabetes and this appears to also be the case during SPC.  The evidence, however, is limited 
with a single study of 92 patients who attended regularly for SPC over 5 years (34).  There was 
a higher odds ratio for both progression of attachment loss [2.9] and tooth loss [3.1] amongst 
those with poor glycaemic control compared to those with good control or no diabetes (34).  
An interaction between smoking and diabetes showed vastly elevated odds ratios for disease 
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progression [6.2] and tooth loss [6.9] in this SPC cohort which again emphasises the 
importance of glycaemic control (and smoking cessation) in the long rather than the short 
term. 
 
Frequency and duration of recall visits 
As we have reported earlier in this review, those patients who undertake more frequent recall 
visits will be likely to demonstrate less clinical attachment loss when compared to those on 
irregular and less frequent programmes of care  
(7,38,72,75,105,108,110,126,127,162).  When SPC is provided every 3 or 4 months over 
periods of up to 12 years, attachment change in the range – 0.85 - +0.25 is expected 
(7,38,72,75,105,110,117,118,126,127,133,162) which suggests that attachment loss 
of >1mm, over years rather than months, is indicative of failing SPC and more frequent recall 
appointments should be considered. 
 
Regarding duration of SPC, for subjects on a programme for < 10 years only those probing 
depths > 7mm were associated with a significantly higher risk for tooth loss in the longer term 
whereas in those subjects on SPC for 10 years or more, probing depths of 5mm and 6mm have 
been reported as being significantly associated with tooth loss.  From a clinical point of view, 
this may indicate that there is a need for increased frequency of SPC as patients’ age as 
recurrent disease becomes more prevalent (92). 
 
Provider of supportive periodontal care 
It is unrealistic to expect specialist periodontists to provide SPC on an indefinite basis and at 
some point in the care management, the patient will be referred back to their general 
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practitioner with a recommended strategy for long-term SPC.  This is an area that has not 
been researched extensively although there is evidence to suggest that at least over the short 
term, stability of probing depths and bleeding on probing remain stable irrespective of where 
the SPC is provided (112).  The longer term observations of Axelsson and Lindhe in their classic 
paper, however, suggest that frequent recall and intensive SPC with a periodontist rather than 
a general dentist will stabilise attachment levels and lead to less tooth loss over 6 years (7).  
Further, in a retrospective cohort study over 11 years, Matuliene and colleagues reported 
that those patients who were treated and followed through SPC in a University clinic 
environment received a greater frequency of recall appointments and had significantly fewer 
probing depths of 5mm when compared to those patients discharged to their private dentists 
(17% vs 30%) (92).  These data don’t allow an unequivocal consensus to be made with any 
confidence regarding the best time during an SPC programme for the specialist to transfer 
responsibility of care to the general dentist and it is possibly best concluded that, until further 
evidence from longitudinal studies becomes available, each case should be considered on an 
individual basis.  The issue of compliance will be covered in more detail in the following 
section but of relevance here is the observation that the majority of 61 patients interviewed 
after periodontal treatment continued to attend their general dentist rather than the 
specialist office for SPC (47).  The interview responses suggested that most patients are 
confident that their own dentist has the ability and skill set to maintain their periodontal 
health and the authors suggested that general dentists who diagnose disease and refer to a 
periodontist may have a particular interest in periodontology, may employ a dental hygienist 
and, therefore, be in a better position and confident to deliver SPC (47). 
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Compliance with supportive care 
Supportive periodontal care 
Compliance with SPC is clearly an essential prerequisite of long-term periodontal stability and 
maintenance of a functional dentition yet the levels of compliance are often below 50% 
(42,47,79,93,102,107,122,145,164).  For example, study recruiting 427 patients treated for 
periodontal disease in a private periodontal practice identified only about 50% of the cohort 
entering SPC and of these, 56% became non-attenders after 20 months and 33% became 
‘erratic’ attenders after around 18 months leaving only 10% attending regular recall after 5-6 
years (41). 
 
There is little doubt that compliance with SPC is a complex issue and one that is of 
multifactorial aetiology (153). Some of these factors such as the patient’s age (120), which 
appears to have a positive association with compliance, are not easily modified although 
there are a number of factors that can be modified or addressed as part of SPC.  A significant 
negative association has been identified between smoking and compliance with SPC by 
Delatola and co-workers (41) and this was reinforced by Ramseier’s group who demonstrated 
that 26% of 429 smokers never returned for SPC after periodontal treatment.  Further, with 
respect to ultimate tooth loss, smokers with an erratic pattern of compliance with SPC 
presented with higher rates of tooth loss (90%) than their non-smoking counterparts (79%) 
whilst smokers who regularly comply with SPC had only a moderately higher rate of tooth loss 
(45%) when compared to non-smokers who regularly comply with SPC (42%) (33).  These 
observations stress the need to address smoking as a risk factor as early as possible in the 
management plan and the need for compliance with more regular recall appointments should 
be stressed to patients who continue to smoke. 
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Supportive implant care (SIC) 
The evidence for the compliance with SIC is not as extensive as for SPC but nevertheless 
suggests a much higher rate of compliance.  For example, a 3-year study of 236 patients with 
540 implants showed compliance rates of 95%, 92% and 86% at 1, 2 and 3 years respectively 
(53) whilst a longer study of 10-years duration demonstrated a compliance rate, albeit with 
only 1 recall appointment/year of 93%.  Cardaropoli et al. followed 74 patients through 
regular recall over 5 years for periodontal and, or implant support and reported a 77% 
compliance rate overall but when patients had implants as well as periodontal treatment, the 
compliance increased to 88% (22).  They suggested that the additional cost and effort of the 
implant provision may have increased motivation to attend regular recall appointments (22). 
 
Adjunctive treatments for supportive periodontal care 
Clearly, repeated instrumentation at non-responding sites during SPC will compromise root 
substance and lead to an increase in tooth sensitivity.  Additional treatments that do not 
necessitate empirical root instrumentation include the application of locally delivered 
antimicrobials which have now been available for over 30 years.  Multiple drugs have been 
incorporated into these products which have been thoroughly investigated but mainly in 
clinical trials involving the treatment of chronic periodontitis rather than in SPC.  When used 
in various formulations (gels, strips, chips, powders, microspheres and fibres) at the 
treatment stage, the mean effect sizes for improvement in clinical attachment have been 
reported as 0.12mm for metronidazole gel (57,78,83,97,109,124,143), 0.16mm for 
chlorhexidine (19,58,61,69,90,142,154), 0.24mm for tetracycline 
(52,55,70,78,83,90,100,151,154) and 0.46mm for minocycline (56,64,78,155,160,163).  It is a 
reasonable assumption of course to anticipate that the effects of using such applications for 
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specific, failing sites during SPC will be similar to those effects reports during the definitive 
treatment stage and although more robust data over extended periods are still needed, there 
is some evidence that suggests a potential role for the reapplication of local antimicrobials 
during SPC.  Repeated applications of microencapsulated minocycline with instrumentation 
at 3 and 6 months during SPC produced sustained and significantly better reductions in 
probing depth after 9 months than instrumentation alone (163).  Similarly, greater 
improvements in probing depths and clinical attachment were seen after 15 months in 
patients with reapplications of a 2% minocycline ointment at 1 month following treatment 
and then at 3-monthly intervals for 12 months (156) although an earlier study of similar design 
had failed to show any advantage of using the antimicrobial over the same period (148). 
 
Slow release doxycycline has also been used as an adjunctive administration during SPC 
(14,39,152).  A significant adjunctive effect in reducing probing depths (with bleeding) >5mm 
and attachment levels at 3 months and a benefit for >6mm probing depths after 6 months 
has been reported, although these effects were not maintained at 12 months which clearly 
demonstrates the relatively short-term benefit in reducing inflammation and suggests that 
their use during SPC might have severe limitations unless reapplications are made (152).  A 
similar observation was also made when a single application of doxycycline was used as an 
adjunct to instrumentation at furcation sites where improvement at 3 months could not be 
sustained after 6 or 12 months and the local delivery failed to reduce the need for additional 
instrumentation at non-responding sites after the 12 months of the study.  Further, local 
application of doxycycline repeated annually over 3 years failed to show any advantage over 
instrumentation alone in maintenance patients either from a clinical or microbiological 
standpoint (14).  These data, therefore, both for minocycline and doxycycline are promising 
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but by no means unequivocal to support the use of these antimicrobials in patients 
undergoing SPC. 
 
Cost-effectiveness of locally delivered antimicrobials 
As part of any future evaluation, consideration must be given to the health economics of using 
local-delivery agents as several reapplications might be indicated over a period of time.  The 
cost-effectiveness, cost benefit and patients willing-to-pay for these treatments are 
paramount to their pragmatic inclusion in a programme of care.  Slots and Jorgensen were 
amongst the first to suggest that the costs of acquiring and administering drugs can be 
relevant in selecting which particular drug regimen to use as an intervention and particularly 
if the agents demonstrate equal efficacy and toxicity (137,139).  Based on this suggestion, we 
reported an economic analysis using a model of SPC with effectiveness data after 12 months 
(17,65), a previously published profile of patients’ characteristics (5), a direct source of 
treatment costs (in the UK) and a rationale for treatment regimens involving the use of 
adjunctive antimicrobials (Fig. 1) (61).  One comparison arm for the model was the provision 
of SPC without adjunctive treatments (Fig. 1).  All of the real economic costs of the initial 
management and subsequent application of local antimicrobials during SPC are shown in 
Table 2 and based on UK economic data from 2009. 
 
The calculations for the cost-effectiveness of localised antimicrobials (minocycline gel, 
chlorhexidine chips or metronidazole gel) during treatment and subsequently during SPC 
showed that the adjunctive use of metronidazole gel is less effective and more expensive than 
the adjunctive use of chlorhexidine chips (and therefore is unlikely to be cost-effective).  The 
adjunctive use of minocycline is more expensive than chlorhexidine chips, but the additional 
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cost, per mm gain in attachment level, is less.  With this particular model, minocycline was 
cost-effective if a patient values a mm in attachment gain on all affected teeth at a minimum 
cost of £1,800 in total. If a patient values this gain between £1,500 and £1,800 then SPC alone 
was cost-effective; for such a patient the additional gain from adjunctive minocycline did not 
justify the additional cost. So in summary, and although this was only a model, the principal 
observation was that localised adjunctive antimicrobials can deliver nearly 1 mm of 
attachment gain throughout SPC, but there is an additional cost.  In general terms, the use of 
localised antimicrobials adds significantly more cost to the SPC programme.  Their effects can 
be clinically significant but the extent to which they are used in SPC will depend 
predominantly on the patients’ willingness-to- pay. 
 
A systematic review and meta-analysis regarding the efficacy of adjunctive local 
administration of antimicrobials in the treatment of peri-mucositis has deduced that within 
the limitations of available studies they do not contribute any statistically significant clinical 
benefits (131).  Several studies examine the effect of local delivery agents on peri-implantitis, 
although these are principally administered at the time of initial treatment rather than during 
the supportive care phase.  The use of minocycline hydrochloride microspheres is promising 
(123,129) and although other agents such tetracycline solution and doxycycline powder (2), 
polymeric tetracycline HCl-containing fibres (95) and ornidazole (94) have been investigated, 
their clinical efficacy and potential role within the supportive care phase remains uncertain 
(68,157).  Further randomised clinical trials are required whilst recognising a potential effect 
of the implant surface texture in compromising the efficacy of any local antimicrobial 
treatment (21).  Furthermore, cultivated submucosal bacterial pathogens from sites of peri-
implantitis have been shown to have a prevalence of resistance to common individual 
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therapeutic antibiotic concentrations of up to 46.7% (119).  Given the current serious global 
concerns over the continued development of antibiotic-resistant bacterial strains (23), other 
adjuvant treatment strategies for SPC and SIC may then need to be explored. 
 
The problem of the non-responding sites in patients undergoing SPC has, more recently, lead 
researchers to investigate the efficacy of novel mechanical, chemical and combinations of 
these methods in periodontal maintenance populations.  For example: 
 
 The relative effectiveness of a manual toothbrush with a fluoride dentifrice and a 
powered toothbrush in combination with a triclosan-containing dentifrice failed to 
demonstrate any clinical or microbiological superiority in 128 subjects after 1, 2 and 3 
years with the patients having been scheduled for 6-monthly recall appointments (15).  
The introduction of a chemical plaque control intervention with 0.05% chlorhexidine and 
0.05% cetylpyridium chloride was found to be effective in reducing plaque levels in a 
placebo-controlled trial recruiting patients who were non-compliant with plaque control 
(Turesky Index >1) during SPC.  The study was only 3 months in duration and so the 
conclusions are quite limited but this observation suggests a possible option for patients 
who may be moved from a more intense, supportive programme to one of longer term 
palliative management (45). 
 
 The use of subgingival air-polishing in recall patients has been investigated both in the 
short- and medium-term studies (98,165).  A 2-month study failed to demonstrate 
differences between interventions in clinical or microbiological outcomes in 5-8mm 
pockets that bled on probing following either air polishing or ultrasonic instrumentation 
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(165); whereas a 12-month trial of 50 patients undergoing recall failed to show 
superiority of air-polishing with an erythitol powder in combination with 0.3% 
chlorhexidine although the air polishing was better accepted by the patients (98). 
 
 Five repeated applications of photodynamic laser were delivered over a 2-week interval 
to a residual probing depths of >5mm in a small cohort of 10 maintenance patients.  The 
variability in outcomes at different follow up time points seen in trials of other 
interventions is mirrored here as the laser intervention produced significant 
improvements in probing depths, attachment and bleeding at 6 months when compared 
to the control group although only the improvement in bleeding was sustained after 12 
months (88).  Photodynamic therapy has also been used in the early management of 
peri-implantitis with clinical outcomes being comparable to conventional 
instrumentation combined with locally-delivered antimicrobials (10,16) although their 
application specifically to SIC has yet to be determined. 
 
 An Nd: YAG laser was used as an adjunct to instrumentation in probing depth sites 
of >5mm in patients on SPC for chronic periodontitis.  The observations at 6-months 
showed no additional benefit from using the laser in this cohort (136). 
 
Although some of the above investigations failed to show any additional benefit from using 
the test treatment no study showed that the test was inferior to the control intervention.  
When the test treatment is used instead of instrumentation (rather than as an adjunct, for 
example with the laser) then if such a treatment is shown to have greater patient acceptability 
25 
 
and is economically more cost-effective, then it may be the preferred option and especially 
so as it has to be reapplied on a regular basis. 
 
A role for systemic antimicrobials? 
First, it is important and pertinent to stress that when SPC or SIC appear to be failing and there 
are identifiable care management or behavioural factors that can be modified (frequency of 
recall, provider of care, smoking habit, standard of plaque control, compliance with the 
programme) then every attempt should be made to address these factors before making any 
further decisions regarding the potential role for systemic antimicrobials or consigning the 
patient to a programme of palliative periodontal management. 
 
The potential role of systemic antimicrobials in the management of chronic periodontitis has 
been a contentious issue amongst the periodontal community and discussion and debate of 
the advantages and disadvantages of this role is outside the remit of this paper.  Clinicians are 
directed to a recent pragmatic article that reviews the guidelines for the use of antibiotics in 
treating chronic periodontitis, the principles of dosing, selection and properties of drugs that 
have been used for this purpose (4).  The authors identify continuing active disease as an 
indication for systemic drug therapy although fail to define this term, either clinically or 
microbiologically.  Nevertheless, their guidance is consistent with the recommendations 
made by van Winkelhoff and Winkel in their excellent Commentary on the subject in which 
they stress that systemic antimicrobials should be used cautiously, and only after the 
determining the bacterial profile so that, for example, the regime of metronidazole and 
amoxicillin can be used for those patients with persistent infection with Porphyromonas 
gingivalis (76,159).  Such reflection of course opens up the potential for using systemic 
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antimicrobials in those carefully selected, compliant patients on SPC or SIC for whom plaque 
control is exemplary and although mechanical treatment has been undertaken to the highest 
standard there remain multiple bleeding and or suppurating pockets in excess of 5mm.  The 
absolutely crucial point here is the need for bacterial profiling to detect and quantify selected 
pathogens that are associated with disease progression prior to antibiotic susceptibility 
surveillance testing which, for patients on SPC, may be undertaken in the long term (every 2 
years) to detect not only persistent but also changes in susceptibility profiles (158).  This 
service is available both at academic institutions (158) and commercially (Micro-IDent®plus, 
Hain Diagnostics, Cookeville, Tennessee, USA) with the emphasis being on the profiling of a 
range of pathogens rather than just two or three known pathogens which tended to be the 
case with the early chair side tests. 
 
Indeed, Actinobacillus actinomycetemcomitans (later Aggregatibacter 
actinomycetemcomitans), Bacteroides forsythus (later Tannerella forsythia) and 
Porphyromonas gingivalis (31) were identified as causative factors for periodontitis based on 
the 1996 World Workshop in Periodontics consensus report.  Current data from the Human 
Oral Microbiome Database (HOMD), however, reflect the technological advances in molecular 
and gene sequencing techniques over the last 2 decades which have identified over 1100 
bacteria taxa in the oral cavity with still 34% known only as uncultivated phylotypes (67).  This 
increase in knowledge of the oral microbiota has served to show increased complexity and 
the multi-species symbiotic relationship that exists within that microbial ecosystem, which is 
also far more complex than previously thought.  Even accepting the added complications of 
potential uncultivable pathogenic species, genetic variation and virulence factors, the current 
dogma still focuses on alteration of the bacterial ecosystem, potentially with antimicrobials 
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to eradicate, or maintain lower levels of periodontopathogens than needed for the 
progression of periodontal disease.  Clinical improvement of periodontitis is associated with 
reductions in the levels, proportions or prevalence of associated pathogens (141) and more 
recent evidence has shown that the significant reductions in 30 of 40 bacterial species 
(including Tannerella forsythia, Treponema denticola and Eubacterium nodatum) following 
periodontal treatment can be maintained at 24 months  (141).  Thus culture and sensitivity 
testing across a range of bacterial species before prescribing antimicrobials certainly has 
potential in selected cases of failing SPC. 
 
At the current time, there is a need for randomised clinical trials to assess the potential role 
of systemic antimicrobials in the supportive care of periodontitis and peri-implantitis (157).  
The down side of systemic antibiotics for controlling the subgingival microflora is of course 
their contribution to the emergence of bacterial resistance and the potential for side effects 
(159) and, unlike the local delivery agents, their effectiveness depends on patient compliance 
with dosing. 
 
Cost-effectiveness of systemic antimicrobials 
The cost-effectiveness of systemic antimicrobials as an adjunct to SPC has previously been 
examined (61).  The analysis compared (i) no intervention at a zero cost and leading to a loss 
of 0.1mm CAL; (ii) SPC without systemic antimicrobials (SPC alone) costing £880 and leading 
to a gain of 0.5mm clinical attachment (that is an additional 0.6mm); (iii) and finally SPC with 
systemic metronidazole and amoxicillin (SPC+AM) costing £885 in total and giving a clinical 
attachment gain of 0.95mm (or 1.05mm in total over no intervention).  Compared to the 
baseline of no intervention, SPC + AM gave an additional cost of £843 per extra mm clinical 
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attachment.  The option of SPC without antimicrobials was only slightly less costly but 
significantly less effective and so not worth considering (and said to be extendedly dominated 
in economic terms).  The data that supported our previous analysis (65) did include 
antimicrobial sensitivity testing but the results of this testing were not used to determine 
which antimicrobials should be prescribed and therefore the effectiveness results reported 
are therefore the same as if no antimicrobial sensitivity testing had been carried out.  In 
addition, the costs calculated did not include any antimicrobial sensitivity testing. 
 
For the purpose of this review, we have extended the previous cost-effectiveness analysis to 
include a 4th arm of SPC + antimicrobials prescribed on the basis of antimicrobial sensitivity 
testing (SPC+AM+ST) in addition to the three arms of no intervention, SPC alone and SPC+AM.  
No published data detailing effectiveness of SPC+AM+ST exist and therefore a hypothetical 
approach was taken to determine the additional effectiveness that adding sensitivity testing 
would need to yield in order to change the conclusions of a cost-effectiveness analysis.  For 
the costs, the previous analysis took the perspective of patient in a direct payment system 
(i.e. all costs are passed onto the patient) and the cost of sensitivity testing was sought from 
two laboratories providing this service.  The costs were $99 and €79.5 converted at a rate of 
$=£0.6955 and €=£0.7740 to give a mean cost of £65.  It was assumed that the cost of 
different antimicrobials provided as a result of sensitivity would be negligibly different to the 
amoxicillin and metronidazole already costed into the SPC+AM arm.  A further assumption 
was that even if sensitivity testing was undertaken, then all patients would still receive 
systemic antimicrobials prescribed ‘blind’ (that is, the results of sensitivity testing would 
influence which antimicrobials were prescribed rather than whether any should be 
prescribed at all). 
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Determining the hypothetical value at which decisions regarding the use of sensitivity testing 
would be influenced can be most easily explained using by plotting clinical effectiveness 
versus cost (Fig. 3).  As the cost is known (£885+65=£950) the point of interest will lie on the 
interrupted vertical line.  If the point lay directly on the intersection of the interrupted and 
solid lines the effectiveness would be 1.027mm.  If the point moved along the vertical 
uninterrupted line so that it was above the solid line, (that is the effectiveness was greater 
than 1.027mm or 0.077mm greater than SPC+AM) then it would always be worth undertaking 
sensitivity testing as this approach would only be slightly more costly for significantly more 
effect than SPC+AM (SPC +AM is extendedly dominated in economic terms).  If the point 
moves along the interrupted line to a point below the solid line but still greater than 
effectiveness of SPC+AM, then a judgement would need to be made as to whether the extra 
effectiveness was worth the extra cost.  If the point moved further down the interrupted line 
to below the effectiveness level of SPC+AM, then SPC+AM would be more effective and less 
costly and so it would be inappropriate to prescribe SPC+AM+ST (SPC+AM+ST would be 
dominated by SPC+AM). 
 
Conclusion 
When SPC appears to be failing despite successful modification of predictive and behavioural 
factors then there are several factors that the clinician may consider.  Increasing the 
frequency of recall visits and reverting to specialist management may help to stabilise the 
disease whilst there is sparse evidence as yet for the benefit of additional treatment methods 
such as laser therapy or air polishing over conventional root instrumentation.  Application of 
local antimicrobials is an option at specific failing sites and systemic application of 
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antimicrobials may be considered as a clinically and cost effective regimen based, where 
possible, upon culture and sensitivity testing. 
 
Abstract for Online Publication 
Supportive periodontal care is a crucial aspect of the management of chronic periodontitis 
and peri-implantitis and is inevitably a long-commitment for both the clinician and the 
patient. The principal goals of supportive care are to achieve a high standard of plaque 
control, minimise bleeding and maintain pockets at less than 6mm.  Gain of attachment 
around natural teeth during SPC has been reported although gain of attachment and gain of 
bone during supportive care may be a more pragmatic and aspirational aim in the longer term.  
Further, we occasionally see patients for whom, despite excellent home and professional care 
(surgical or non-surgical) including the management of risk factors, SPC appears to be failing 
and the clinician needs to consider further management options.  This review considers in 
particular the options of using local or systemically-delivered antimicrobials to eradicate 
periodontal and peri-implant disease progression and discusses the extent to which culture 
and sensitivity testing prior to the prescription of systemically-delivered antimicrobials may 
be a cost-effective alternative to prescribing ‘blind’. 
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Study/Year No. of 
participants 
Mean age 
(SD) range 
Treatment Supportive care and recall Clinical effectiveness 
Nyman et al.  (1975) 
(105) 
20 Unreported OHI and surgical 
pocket elimination 
Test group: Professional 
tooth cleaning every 2 
weeks for 2 years.  Control 
group: Scale and polish 
every 6 months 
Test group: mean (SE) gain of CA 0.1 (0.25mm) at years. Control group: mean (SE) 
loss of CA – 2.2 (0.39) at years. CAL measurements relative to pre-surgical 
measurements 
 
 
Ramfjord et al. 
(1975) (117) 
82 39.6 (13.1) 
 [19-61] 
OHI, ScRP followed 
by either: curettage 
OR MWF OR pocket 
elimination with 
split-mouth design 
Prophylaxis every 3 months 
for 5 years 
Curettage Buccal    Lingual     Interproximal sites 
-0.50 -0.65 -0.64 
MWF -0.26 -0.36 -0.23 
Pocket elimination -0.33 -0.24 -0.27 
CAL (mm) between 1 and 5 years: 
 
 
 
 
 
 
Axelsson & Lindhe 
(1981) (6) 
90 52 OHI, ScRP followed 
by MWF 
Recall group: 30 min. 
appointment for Sc OHI 
every 2 months for 2 years 
and then every 3 months for 
4 years. Non-recall group: 
referred to dentist with 
written instructions for 
plaque control programme 
Baseline taken as 2 months after surgery                                                                        
Mean (SD) No. teeth 
Recall Baseline 19.6 (7.0) 
6 years 19.4 (7.0) 
Non-recall Baseline  18.0 (5.0) 
6 years 17.3 (5.5) 
∆mean CAL during 6 year period of SPC 
 Recall +0.2 
Non-recall -1.8 
 
 
Pihlstrom et al. 
(1981) (110) 
17 43 [22-59] OHI, ScRP followed 
by MWF for half 
mouth 
60 min. appointments with 
hygienist every 3-6 months 
for supra and subgingival 
scaling for 4 years 
8 teeth extracted during active therapy. 6 teeth extracted during SPC.  Change in 
mean CAL (mm) during 4 years of SPC according to initial pocket depth. 
 ScRP MWF 
1-3mm -0.22 -0.23 
4-6mm -0.27 -0.25 
≥7mm -0.47 -0.07 
 
Ramfjord et al. 
(1987) (118) 
90 [24-68] OHI, ScRP followed 
by pocket 
elimination, 
curettage, ScRP or 
MWF mouth, split 
mouth design 
Recall for prophylaxis every 
3 months for 5 years 
 
∆CAL (mm) during SPC according to initial pocket depth 
 PE C ScRP MWF 
1-3 mm -0.53 -0.64 -0.62 -0.64 
4-6mm -0.49 -0.42 -0.57 -0.43 
≥7mm -0.26 -0.41 -0.40 -0.53 
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Study/Year No. of 
participants 
Mean age 
(SD) range 
Treatment Supportive care and recall Clinical effectiveness 
Kaldahl et al. 
(1988) (75) 
82 43.5 Random allocation to 
treatment of quadrants by 
coronal scaling (cs), 
subgingival ScRP, SRP+MWF 
or osseous resection with 
ScRP 
Recall with hygienist every 3 
months for 2 years; ScRP in 3 
quadrants. CS and prophylaxis 
provided to quadrant initially 
treated by CS. 
∆mean CAL (mm) during SPC according to initial pocket depth (mm) 
 CS ScRP MWF OR 
1-4 -0.33 -0.29 -0.34 -1.26 
5-6 -0.16 -0.02 -0.12 -0.01 
≥7 -0.25 -0.03 -0.06 0.11 
 
Cortellini et al. 
(1994) (32) 
23 [18-56] OHI, ScRP followed by GTR 
at target sites of attachment 
loss ≥ 6mm. 
Intesive OHI for 1 year, then: 
Group A (n=15) 
OHI, ScRP from hygienist every 3 
months for 3 years. 
Group B (n=8) 
Sporadic SPC from general 
dentist. 
∆mean CAL (mm) during SPC 
Group A -0.01 
Group B -2.80 
Weigel et al. 
(1995) (162) 
24 54 
[40-79] 
Hygiene phase and GTR Supragingival ScRP and rinsing 
with 0.1% CHX every 3-6 months 
post-surgery. 
∆mean CAL (mm) during SPC 
Teeth  Subjected to GTR -1.05 
 Sites subjected to GTR -0.94 
Cugini et al. 
(2000) (38) 
32 48 (11) 
[29-71] 
ScRP Full mouth scaling and instruction 
in home care at 3 monthly 
intervals for 12 months post-
therapy. 
 
∆mean CAL (mm) -0.03 between post-treatment monitoring at 3 and 12 
months. 
 
Jenkins et al. 
(2000) (72) 
39 [34-67] ScRP Allocated to one of two SPC 
regimes: Coronal scaling (CS) 
Subgingival scaling (SS) at 3 
monthly intervals for 1 year. 
∆mean CAL (mm) at 12 months 
CS -0.13 (0.19) 
SS -0.04 (0.18) 
Last observation carried forward for CS loser sites ≥2mm LOA that required 
SS 
 
Becker et al. 
(2001) (12) 
16 42  
[30-57] 
ScRP alone  
ScRP & MWF 
ScRP & Osseous resection 
Post-surgery – weekly for 6 weeks 
for prophylaxis, then recall every 
3 months for 5 years. Details of 
SPC intervention not reported. 
∆mean CAL (mm) during 5 years SPC relative to initial pocket depth 
 ScRP MWF OR 
1-3 -0.07 -0.35 -0.39 
4-6 0.01 -0.72 -0.26 
≥7 -0.09 -0.49 -0.97 
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Implants 
Costa et al. (2012) 
(37) 
212 49.7 (11.75) [20-65] Implant Placement 5 SPC visits over at least 5 
years 
Mucositis progressed to implantitis: 
Group receiving SPC-18.0% of subjects. 
Group not receiving SPC-43.9% of subjects. 
 
 
Study/Year No. of 
participants 
Mean age 
(SD) range 
Treatment Phase Supportive care  Clinical outcomes 
Rosling et al. 
(2001) (126) 
170 45.5 (8.4) ScRP OHI and subgingival instrumentation of pockets ≥5mm 
and BoP. Recall 3-4 visits a year for 12 years. 
Average of 1.9 teeth/subject lost after 12 years of SCP. 
Cumulative ∆CAL (mm) over 12 years SPC according to 
sites: 
Buccal -0.85 
Lingual -0.85 
Approximal -0.80 
Total -0.80 
 
Rosling et al. 
(2001) (127) 
148 44.5 (8.6) ScRP Recall for prophylaxis every 3-4 months for 12 years 
with ScRP at sites ≥5mm sites exited if CA loss ≥2mm 
at ≥4 teeth. 
Average of 2.4 teeth/subject lost after 12 years SPC. 
Cumulative ∆CAL over 12 years SPC = -0.87mm. 
 
Serino et al. 
(2001) (133) 
64 Unreported ScRP only or ScRP & MWF 
 
 
OHI and subgingival instrumentation of pockets ≥5mm 
and BoP. Recall 3-4 visits a year for 13 years. 
Mean (SD) tooth loss during SPC 
ScRP            MWF 
1.6 (1.7)      0.6 (1.1) 
∆mean CAL (mm) during 12 years SPC 
ScRP            MWF 
-0.26            -0.25 
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Table 2 
 
Periodontal management  Cost £ 
Initial assessment 100 
Non-surgical management based on 4 x 45 minute appointments with a dental 
hygienist 
500 
Prescription and placement of 5 chlorhexidine chips (PerioChips1) 170 
Prescription and placement of 3 chlorhexidine chips (PerioChips1) 126 
Prescription and placement of 1 chlorhexidine chip (PerioChips1) 82 
Cost of 4 applications of minocycline gel (Dentomycin3) 270 
Cost of 2 applications of metronidazole gel (Elyzol2) 140 
Maintenance visit with dental hygienist 1 x 20 minutes 70 
  
1   Dexcel Pharma Ltd, UK.   
2   Colgate-Palmolive, UK. 
3 Blackwell Supplies, UK.  
SPC – Supportive periodontal care 
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Figure 1 
 
 
 
 
 
        
 
 
        
 
 
        
 
 
        
 
 
        
 
 
 
 
 
 
 
  
Patient with moderate to severe chronic periodontitis 
Non-surgical periodontal treatment 
 
Supportive periodontal care and re 
assessment 
Option 2: 
SPC with application of local delivery 
agents to sites with probing depths > 
6mm 
Option 1: 
Further SPC alone 
 
SPC visit at 3 months:   
Re-apply local delivery agent to 3 
residual sites > 6mm 
 
SPC visit at 3 months 
SPC visit at 6 months: 
Re-apply local delivery agent to 1 
residual site > 6mm 
 
 
SPC visit at 6 months 
SPC visit at 9 months 
 
 
SPC visit at 9 months 
SPC visit at 12 months and re-
assessment 
 
SPC visit at 12 months and re-
assessment 
  Continue with SPC according to clinical 
needs 
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Figure 2 
 
 
 
 
 
        
 
 
        
 
 
        
 
 
        
 
 
        
 
 
 
 
 
 
 
  
Patient with moderate to severe chronic periodontitis 
Non-surgical periodontal treatment 
 
Supportive Periodontal Care and re -
assessment 
Option 2: 
Amoxicillin 250 mg 
Metronidazole 375mg 
3 x a day for one week 
 
Option 1: 
Further SPC alone 
 
 
SPC visit at 3 months:  
 
SPC visit at 3 months 
SPC visit at 6 months SPC at 6 months 
SPC visit at 9 months 
 
 
SPC visit at 9 months 
SPC visit at 12 months and re-
assessment 
 
SPC visit at 12 months and re-
assessment 
  Continue with supportive periodontal  
  care according to clinical needs 
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Figure 3 
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SPC+AM 
No SPC 
 
SPC alone 
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Legends 
Table 1 
Tooth loss and change in attachment during supportive periodontal care in 14 studies of 
periodontal disease and 1 study of implants.  [Adapted from Gaunt et al.2008 (P38)]. 
Key: ∆CAL, change in clinical attachment level; BoP, bleeding on probing; C, curettage; CA, 
clinical attachment; CHX, chlorhexidine; CS, coronal scaling; GTR, guided tissue regeneration; 
LOA, loss of attachment; MWF, modified Widman flap; OHI, oral hygiene instruction; OR, 
osseous resection; PE, pocket elimination; RCT, randomized controlled trial; ScRP, scaling and 
root planning, standard deviation; SE, standard error; SPC, supportive periodontal care. 
 
Table 2 
Real economic costs for the management and provision of SPC by a periodontal specialist for 
a patient with chronic periodontitis. Management includes assessment, non surgical 
treatment, and prescription of 3 different locally-delivered antimicrobials during 12 months 
of SPC.  (Data collected from 4 specialist practitioners based at different practices in the UK 
with costs given as British pounds 2009). 
 
Figure 1 
Suggested treatment protocol for the use of adjunctive, locally-delivered antimicrobials in the 
management of moderate-to-advanced chronic periodontitis. The model provides 2 Options 
for the use of either SPC with or without locally-delivered preparations. It is assumed that 
following a period of SPC there remain a number of pockets of >6mm.  The locally-delivered 
agents are then applied to these persistent pockets of ≥6mm throughout a further period of 
SPC over 12 months. It is also assumed that the local agents are used according to the 
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manufacturers’ instructions and, for example, unused gel or pastes may be reapplied and 2-
weekly intervals for increased effectiveness and to avoid wastage. 
 
Figure 2 
Suggested treatment protocol for the use of adjunctive, systemic antimicrobials in the 
management of moderate-to-advanced chronic periodontitis. The model provides 2 Options  
for the use of either SPC with or without systemic antimicrobials.  It is assumed that following 
a period of SPC there remain a number of pockets of >6mm. The systemic dose of amoxicillin 
250 mg with metronidazole 375mg, 3 x a day for one week  is then used only once. 
 
Figure 3 
Cost and effectiveness of different options of prescribing systemic antimicrobials (AM) as part 
of the SPC regimen, with and without sensitivity testing. For explanation – see text. 
 
